Mandate

Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB

Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.

Epiluvac’s technology platform combined with Veeco’s global go-to-market capabilities is expected to create a significant long-term growth driver for Veeco. Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs.

Vinge's team consisted of, among others, Jonas Bergström, Carl Sander, Stina Bengtsson and Robin Sultani (M&A), Sofia Bergenstråhle and Arvid Axelryd (IP), Anna Ståhlklo and Jonna Skog (Employment), Victor Ericsson and Emelie Svanberg (Tax), Nicklas Thorgerzon (IT & GDPR) and Jasmina Skandrani (Project Assistant).

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025